KALV vs KALA vs RARE vs OCUL

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -18. 7% for Ocular Therapeutix, Inc. (OCUL). Analysts rate KalVista Pharmaceuticals, Inc. (KALV) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, KalVista Pharmaceuticals, Inc.

(KALV) delivered a total return of +5. 9%, compared to -100. 0% for KALA BIO, Inc. (KALA). Over 10 years, the gap is even starker: KALV returned +154. 5% versus KALA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), KalVista Pharmaceuticals, Inc.

(KALV) is the lower-risk stock at 0. 82β versus KALA BIO, Inc. 's 2. 09β — meaning KALA is approximately 154% more volatile than KALV relative to the S&P 500. On balance sheet safety, KalVista Pharmaceuticals, Inc. (KALV) carries a lower debt/equity ratio of 7% versus 3% for KALA BIO, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus -18. 7% for Ocular Therapeutix, Inc. (OCUL). On earnings-per-share growth, the picture is similar: KALA BIO, Inc. grew EPS 59. 8% year-over-year, compared to -16. 4% for Ocular Therapeutix, Inc.. Over a 3-year CAGR, RARE leads at 22. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ultragenyx Pharmaceutical Inc.

(RARE) is the more profitable company, earning -85. 4% net margin versus -141. 1% for KALA BIO, Inc. — meaning it keeps -85. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RARE leads at -79. 5% versus -150. 6% for KALA. At the gross margin level — before operating expenses — OCUL leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, KalVista Pharmaceuticals, Inc.

(KALV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 82), +154. 5% 10Y return). KALA BIO, Inc. (KALA) carries a higher beta of 2. 09 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KALV: +154. 5%, KALA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KALV is a small-cap quality compounder stock; KALA is a small-cap quality compounder stock; RARE is a small-cap high-growth stock; OCUL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.